The American Association for Respiratory Care Corporate Partner Program is comprised of best-in-class organizations interested in supporting the goals and work of the Association. The program aims to give respiratory care providers information, insights, and innovative approaches to improve performance and advance the health of their patients. Together, this move will strengthen each of us in all of our endeavors. It is with great pride that we present our Corporate Partners.
Cardinal Health, (NYSE:CAH), is the leading provider of respiratory products to health care providers in the United States. Cardinal Health businesses develop, manufacture, package and market products for patient care; develop drug-delivery technologies; distribute pharmaceuticals, medical-surgical and laboratory supplies; and offer consulting and other services that improve quality and efficiency in health care. Headquartered in Dublin, Ohio, Cardinal Health employs approximately 50,000 people on five continents and produces annual revenues of more than $47 billion. Cardinal Health is ranked number 19 on the current Fortune 500 list and was named one of “The World’s Best”companies by Forbes magazine in 2002.
Sepracor Inc. is widely recognized in the respiratory care category as the makers of XOPENEX® (levalbuterol HCl) inhalation solution for the treatment or prevention of bronchospasm in patients 6 years of age and older with reversible obstructive airway disease, such as asthma. Sepracor is a research-based pharmaceutical company dedicated to treating and preventing human disease through the discovery, development, and commercialization of innovative pharmaceutical products that are directed toward serving unmet medical needs. Sepracor's drug development program has yielded an extensive portfolio of pharmaceutical compound candidates, including candidates for the treatment of respiratory, urology, and central nervous system disorders. Sepracor’s corporate headquarters are located in Marlborough, MA.
Masimo, (NASDAQ: MASI) develops innovative monitoring technologies that significantly improve patient care-helping solve “unsolvable” problems. In 1995, the company debuted Measure-Through Motion and Low Perfusion pulse oximetry, known as Masimo SET, and with it virtually eliminated false alarms and increased pulse oximetry’s ability to detect life-threatening events. More than 100 independent and objective studies demonstrate Masimo SET provides the most trustworthy SpO2 and pulse rate measurements even under the most difficult clinical conditions, including patient motion and low peripheral perfusion. In 2005, Masimo introduced Masimo Rainbow SET, a breakthrough noninvasive blood constituent monitoring platform that can measure many blood constituents that previously required invasive procedures. Rainbow SET continuously and noninvasively measures total hemoglobin (SpHbTM) and oxygen content (SpOCTM) (both pending FDA clearance), carboxyhemoglobin (SpCO(r)), methemoglobin (SpMet(r)), and PVITM, in addition to oxyhemoglobin (SpO2), perfusion index (PI) and pulse rate, allowing early detection and treatment of potentially life-threatening conditions. Founded in 1989, Masimo has the mission of “Improving Patient Outcomes and Reducing Cost of Care by Taking Noninvasive Monitoring to New Sites and Applications.” Additional information about Masimo and its products may be found at www.masimo.com.
With the acquisition of Diagnostics Products Corporation and Bayer Diagnostics, Siemens Medical Solutions is the first full service diagnostics company. By leveraging the strengths of all three companies, Siemens Medical Solutions Diagnostics is in the unique position to improve operational and financial outcomes across the continuum of care.
Siemens Medical Solutions Diagnostics offers a broad portfolio of performance-driven diagnostic solutions that assist in the diagnosis, monitoring and management of disease.
Our products and services bring together the right balance of science, technology, and practicality across the healthcare continuum to empower medical professionals with the vital information they need to deliver better, more personalized healthcare to patients around the globe.
The depth and breadth of our diagnostic systems—immunoassay, clinical chemistry, automation, molecular, hematology, and point-of-care—combined with a robust menu and IT offering deliver integrated, customer-focused solutions designed to meet the needs of any size laboratory, today and tomorrow.
Boehringer Ingelheim Pharmaceuticals, Inc., based in Ridgefield, CT, is the largest U.S. subsidiary of Boehringer Ingelheim Corporation (Ridgefield, CT) and a member of the Boehringer Ingelheim group of companies. The Boehringer Ingelheim group of companies ranks among the 20 leading pharmaceutical corporations in the world. Headquartered in Ingelheim, Germany, it operates globally with 156 affiliates in 44 countries and a total of about 32,000 employees. Since it was founded in 1885, the family-owned company has been committed to researching, manufacturing and marketing novel products of high therapeutic value for human and veterinary medicine. In 2002, Boehringer Ingelheim posted net sales of $7.2 billion (7.6 billion euro) while spending about one fifth of net sales in its largest business segment Prescription Medicines on research and development.
Covidien, formerly Tyco Healthcare, is a global $10 billion manufacturer of leading medical devices and supplies, imaging products and pharmaceuticals. The Company employs more than 43,000 people worldwide and is dedicated to working with medical professionals to improve patient outcomes. Its portfolio of leading brands includes Nellcor, Puritan Bennett, Mallinckrodt, Autosuture, Kendall, Syneture and Valleylab.
Monaghan Medical Corporation is a global leader in the manufacture and sale of aerosol drug delivery devices and asthma management products as well as a supplier to major pharmaceutical companies involved with respiratory medicine in the United States. The company’s strength lies in its science based approach to developing cost efficient, outcome based products for aerosolized drug delivery including the well-known brand names AeroChamber Plus® Valved Holding Chamber, AeroVent® Collapsible Holding Chamber, AeroEclipse® Breath Actuated Nebulizer, and TruZone™ Peak Flow Meter. Detailed clinical and contact information can be found on the company's website, www.monaghanmed.com.
Respirionics is a leading developer, manufacturer and distributor of products and programs that serve the global sleep and respiratory markets. Focusing on emerging market needs, the Company is committed to providing solutions to help improve outcomes for patients, clinicians and health care providers. Respironics markets its products in 131 countries and employs over 4,600 associates worldwide. Further information can be found on the Company’s Web site: www.respironics.com.
IKARIA™ (formerly known as INO Therapeutics) is a uniquely positioned, fully integrated pharmaceutical company. The company possesses strong scientific capabilities in both pharmaceuticals and drug delivery devices, such as our flagship product INOmax® (nitric oxide) for inhalation and the INOvent®. The focus of the company is upon attaining leadership in the in-patient critical care market, by bringing to our customers innovative products that meet the needs of the critical care patient and the professionals who care for them.
Maquet Critical Care provides innovative Servo mechanical ventilator medical technology, ventilation knowledge, and complete product services for critical care and sub-acute care providers. Maquet provides educational programs to achieve tangible, sustainable patient outcomes while contributing to cost-effectiveness. Maquet Critical Care maintains a total focus on ventilation, from R&D through sales and service. Maquet works closely with their customers to provide total ventilation solutions. This is based on a tradition of electromedical devices going back more than 30 years.
VIASYS Healthcare Inc. is a global market leader in health-care technology, distinction that is built on a solid history of innovation, superior product performance, and commitment to customer service. VIASYS Healthcare Inc. comprises many well-established companies that are recognized for market leadership in the areas of respiratory care, neurology, vascular medicine, critical care and the medical and surgical product markets.
ResMed is a leading respiratory medical device manufacturer, specializing in products for the diagnosis and treatment of sleep disordered breathing (SDB). ResMed operates through direct offices in the United States and several other countries, and through a network of distributors in more than 60 other countries.
When ResMed was formed in 1989, its primary purpose was to produce a device for treating obstructive sleep apnea. Developed in 1981 by Professor Colin Sullivan and colleagues at the University of Sydney, nasal continuous positive airway pressure (CPAP) provided the first successful noninvasive treatment of OSA. Since 1989, ResMed has maintained its focus on SDB, which is gaining greater public and physician awareness. Operations have grown dramatically through the introduction of a number of highly innovative product lines.
Dräeger Medical AG & Co. KG is one of the world’s leading manufacturers of medical equipment, the largest division of Drägerwerk AG (history dates back to 1889) and a 65:35 joint venture company between Drägerwerk AG and Siemens AG. The Company offers products, services and integrated CareArea™ Solutions throughout the patient care process—Emergency Care, Perioperative Care, Critical Care, Perinatal Care and Home Care. Dräger Medical provides innovative solutions for acute patient care which are the result of a clear focus on core competencies, a close dialog with customers, over a century of experience in the market, and continuous investment in R&D. With U.S. headquarters in Telford, Pennsylvania and world headquarters in Lübeck, Germany, Dräger Medical employs nearly 6,000 people worldwide.
Discovery Labs is a biotechnology company developing its proprietary surfactant technology as Surfactant Replacement Therapies (SRT) for respiratory diseases. Discovery Lab's technology produces a precision-engineered surfactant that is designed to closely mimic the essential properties of natural human lung surfactant. Discovery Labs believes that through its technology, pulmonary surfactants have the potential, for the first time, to address respiratory diseases where there are few or no approved therapies available. Discovery Lab's SRT pipeline is Surfaxin® for RDS and BPD in premature infants, and Aerosurf™ for neonatal respiratory failures. SRT technology is also being developed to address the various respiratory conditions affecting pediatric, young adult, and adult patients suffering from ARDs, ALI, and COPD. Discovery Labs is located in Warrington , PA.
DEY, L.P. is a specialty pharmaceutical company focused on the development, manufacturing and marketing of prescription drug products for the treatment of respiratory diseases, respiratory-related allergies, and emergency care medicine. DEY is best known as one of the largest US manufacturers of sterile, unit-dose inhalation solution products. DEY is located in Northern California’s Napa Valley with a distribution facility and customer service in Allen, Texas. DEY, L.P. is an affiliate of Merck KGaA, Darmstadt, Germany.
GE Healthcare provides solutions for tailored therapy that are helping shape a new age of patient care. Advance critical care ventilation and monitoring integration in the Engstrom Carestation features new breakthrough methods in ventilation monitoring with SpiroDynamiacs and FRC INview. Other solutions include a noninvasive and highly flexible approach to heliox therapy using the Aptaer Heliox Delivery System . And the Centiva/5 Critical Care Ventilator combines a compact size with high levels of performance. Headquartered in the United Kingdom, GE Healthcare is a $17 billion unit of General Electric Company (NYSE:GE). Worldwide, GE Healthcare employs more than 46,000 people committed to serving healthcare professionals and their patients in more than 100 countries.
